AgingResearch.NewsJoin free

SC79

SC79 has been studied in 1 paper since 2024: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Jan 10, 2024: “DsbA-L ameliorates renal aging and renal fibrosis by maintaining mitochondrial homeostasis”.

Intervention

1 paper studies it1 findingUpdated

PubChemChEBI

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Animals1

What did studies of SC79 find?

1

Studies of SC79 measured 1 outcome; the most studied are renal aging (1 study).

Renal aging

downin mice1

1 study

  1. SC79 decreases renal aging in mice.

    “Accelerated renal aging could be alleviated by an AKT agonist (SC79) or a mitochondrial protector (MitoQ) in mice with D-gal-induced aging.”

    Animalsin D-gal-treated mice

    DsbA-L ameliorates renal aging and renal fibrosis by maintaining mitochondrial homeostasis

    Acta pharmacologica Sinica

Latest

Related